ES2835499T3 - Metotrexato para la vitreorretinopatía proliferativa - Google Patents
Metotrexato para la vitreorretinopatía proliferativa Download PDFInfo
- Publication number
- ES2835499T3 ES2835499T3 ES15827946T ES15827946T ES2835499T3 ES 2835499 T3 ES2835499 T3 ES 2835499T3 ES 15827946 T ES15827946 T ES 15827946T ES 15827946 T ES15827946 T ES 15827946T ES 2835499 T3 ES2835499 T3 ES 2835499T3
- Authority
- ES
- Spain
- Prior art keywords
- methotrexate
- composition
- injection
- erm
- vrp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000006785 proliferative vitreoretinopathy Effects 0.000 title claims abstract description 81
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title claims abstract description 66
- 229960000485 methotrexate Drugs 0.000 title claims abstract description 65
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 title claims abstract description 41
- 206010038934 Retinopathy proliferative Diseases 0.000 title claims abstract description 41
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 title claims abstract description 41
- 238000002347 injection Methods 0.000 claims abstract description 53
- 239000007924 injection Substances 0.000 claims abstract description 53
- 208000001351 Epiretinal Membrane Diseases 0.000 claims abstract description 51
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 230000003442 weekly effect Effects 0.000 claims abstract description 11
- 206010038848 Retinal detachment Diseases 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 41
- 238000001356 surgical procedure Methods 0.000 claims description 41
- 230000004264 retinal detachment Effects 0.000 claims description 36
- 208000002367 Retinal Perforations Diseases 0.000 claims description 13
- 230000002980 postoperative effect Effects 0.000 claims description 12
- 238000011161 development Methods 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 7
- 206010038897 Retinal tear Diseases 0.000 claims description 5
- 208000032843 Hemorrhage Diseases 0.000 claims description 4
- 208000019793 rhegmatogenous retinal detachment Diseases 0.000 claims description 4
- 230000005923 long-lasting effect Effects 0.000 claims 1
- 208000036866 Vitreoretinopathy Diseases 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 23
- 210000001508 eye Anatomy 0.000 description 23
- 210000001525 retina Anatomy 0.000 description 16
- 238000011282 treatment Methods 0.000 description 14
- 239000012528 membrane Substances 0.000 description 12
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 9
- 230000004438 eyesight Effects 0.000 description 8
- 238000013268 sustained release Methods 0.000 description 8
- 239000012730 sustained-release form Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000004304 visual acuity Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 208000031471 Macular fibrosis Diseases 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000227 bioadhesive Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000012057 exposure response modelling Methods 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010037508 Punctate keratitis Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010041951 Staphyloma Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 210000004155 blood-retinal barrier Anatomy 0.000 description 2
- 230000004378 blood-retinal barrier Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010063341 Metamorphopsia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- TXNRYTCUNXUNFH-QPHDTYRISA-N N(3)-fumaramoyl-(S)-2,3-diaminopropanoic acid zwitterion Chemical compound OC(=O)[C@@H](N)CNC(=O)\C=C\C(N)=O TXNRYTCUNXUNFH-QPHDTYRISA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010073286 Pathologic myopia Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 229940003677 alphagan Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011257 definitive treatment Methods 0.000 description 1
- 208000001309 degenerative myopia Diseases 0.000 description 1
- 230000004340 degenerative myopia Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- -1 endolaser Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 229940033835 flonase Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 229940029200 iluvien Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 229940060928 lacrisert Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940083224 ozurdex Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000001127 pigmented epithelial cell Anatomy 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000002278 reconstructive surgery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229940061341 retisert Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002301 subretinal fluid Anatomy 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 239000005460 tetrahydrofolate Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 229940053728 vitrasert Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462030778P | 2014-07-30 | 2014-07-30 | |
| PCT/US2015/042951 WO2016019165A1 (en) | 2014-07-30 | 2015-07-30 | Methotrexate for proliferative vitreoretinopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2835499T3 true ES2835499T3 (es) | 2021-06-22 |
Family
ID=55218325
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15827946T Active ES2835499T3 (es) | 2014-07-30 | 2015-07-30 | Metotrexato para la vitreorretinopatía proliferativa |
| ES20191599T Active ES2969374T3 (es) | 2014-07-30 | 2015-07-30 | Metotrexato para la vitreorretinopatía proliferativa |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20191599T Active ES2969374T3 (es) | 2014-07-30 | 2015-07-30 | Metotrexato para la vitreorretinopatía proliferativa |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10098884B2 (enExample) |
| EP (3) | EP3174540B9 (enExample) |
| JP (3) | JP7097181B2 (enExample) |
| CA (2) | CA3200870A1 (enExample) |
| ES (2) | ES2835499T3 (enExample) |
| WO (1) | WO2016019165A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2835499T3 (es) * | 2014-07-30 | 2021-06-22 | Massachusetts Eye & Ear Infirmary | Metotrexato para la vitreorretinopatía proliferativa |
| WO2018027044A1 (en) * | 2016-08-05 | 2018-02-08 | Schepens Eye Research Institute | Idelalisib for treating proliferative vitreoretinopathy and abnormal intraocular neovascularization |
| US11739326B2 (en) | 2017-11-14 | 2023-08-29 | Massachusetts Eye And Ear Infirmary | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
| CN114423432A (zh) * | 2019-09-13 | 2022-04-29 | 奥尔德拉医疗公司 | 甲氨蝶呤的眼用制剂 |
| CN115804665A (zh) * | 2022-12-13 | 2023-03-17 | 南昌大学附属眼科医院 | 一种tpvr动物模型的建立方法 |
| WO2024129979A1 (en) * | 2022-12-14 | 2024-06-20 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
| US11911385B1 (en) | 2022-12-14 | 2024-02-27 | Aldeyra Therapeutics, Inc. | Methotrexate treatment methods |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020032734A1 (en) | 2000-07-26 | 2002-03-14 | Rhoads Geoffrey B. | Collateral data combined with user characteristics to select web site |
| AUPQ496500A0 (en) | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
| US20040253243A1 (en) * | 2003-01-21 | 2004-12-16 | David Epstein | Aptamer therapeutics useful in ocular pharmacotherapy |
| US20050255144A1 (en) | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| WO2005095464A1 (ja) * | 2004-04-02 | 2005-10-13 | Denki Kagaku Kogyo Kabushiki Kaisha | ヒアルロン酸－メトトレキサート結合体 |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| ATE439123T1 (de) | 2004-07-02 | 2009-08-15 | Novagali Pharma Sa | Verwendung von emulsionen zur intra- und periocularen injection |
| MX344532B (es) * | 2004-10-01 | 2016-12-19 | Ramscor Inc | Composiciones de farmaco de liberacion sostenida convenientemente implantables. |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US20090081277A1 (en) | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Pharmaceutical formulations and methods for treating ocular conditions |
| US20110200662A1 (en) | 2008-10-22 | 2011-08-18 | Arnold Glazier | Method For The Treatment Of Proliferative Disorders Of The Eye |
| US9770414B2 (en) | 2010-05-13 | 2017-09-26 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| US20140105956A1 (en) * | 2012-10-11 | 2014-04-17 | Rupak BANERJEE | Biodegradable polymer based microimplant for ocular drug delivery |
| EP4566672A3 (en) * | 2012-11-08 | 2025-08-13 | Clearside Biomedical Inc. | Methods for the treatment of ocular disease in human subjects |
| ES2835499T3 (es) * | 2014-07-30 | 2021-06-22 | Massachusetts Eye & Ear Infirmary | Metotrexato para la vitreorretinopatía proliferativa |
-
2015
- 2015-07-30 ES ES15827946T patent/ES2835499T3/es active Active
- 2015-07-30 CA CA3200870A patent/CA3200870A1/en active Pending
- 2015-07-30 EP EP15827946.3A patent/EP3174540B9/en active Active
- 2015-07-30 WO PCT/US2015/042951 patent/WO2016019165A1/en not_active Ceased
- 2015-07-30 US US15/500,351 patent/US10098884B2/en active Active
- 2015-07-30 EP EP23205570.7A patent/EP4311575A3/en not_active Withdrawn
- 2015-07-30 CA CA2991921A patent/CA2991921C/en active Active
- 2015-07-30 ES ES20191599T patent/ES2969374T3/es active Active
- 2015-07-30 JP JP2017505180A patent/JP7097181B2/ja active Active
- 2015-07-30 EP EP20191599.8A patent/EP3791883B1/en active Active
-
2017
- 2017-09-08 US US15/699,559 patent/US10272089B2/en active Active
-
2019
- 2019-04-29 US US16/397,562 patent/US10828306B2/en active Active
-
2020
- 2020-10-30 US US17/085,907 patent/US20210283135A1/en not_active Abandoned
- 2020-12-07 JP JP2020202357A patent/JP2021059554A/ja active Pending
-
2023
- 2023-07-13 JP JP2023114963A patent/JP2023145527A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200085827A1 (en) | 2020-03-19 |
| US20210283135A1 (en) | 2021-09-16 |
| EP3791883A1 (en) | 2021-03-17 |
| US10828306B2 (en) | 2020-11-10 |
| EP4311575A2 (en) | 2024-01-31 |
| US20170216294A1 (en) | 2017-08-03 |
| EP3174540A1 (en) | 2017-06-07 |
| WO2016019165A1 (en) | 2016-02-04 |
| EP3791883B1 (en) | 2023-10-25 |
| JP7097181B2 (ja) | 2022-07-07 |
| CA3200870A1 (en) | 2016-02-04 |
| JP2021059554A (ja) | 2021-04-15 |
| EP3174540B1 (en) | 2020-09-02 |
| JP2017523974A (ja) | 2017-08-24 |
| EP3174540B9 (en) | 2021-05-05 |
| US10272089B2 (en) | 2019-04-30 |
| EP3174540A4 (en) | 2018-04-04 |
| JP2023145527A (ja) | 2023-10-11 |
| US20170368067A1 (en) | 2017-12-28 |
| ES2969374T3 (es) | 2024-05-17 |
| CA2991921A1 (en) | 2016-02-04 |
| US10098884B2 (en) | 2018-10-16 |
| CA2991921C (en) | 2023-08-08 |
| EP4311575A3 (en) | 2024-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2835499T3 (es) | Metotrexato para la vitreorretinopatía proliferativa | |
| Jaffe et al. | Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device | |
| US7083803B2 (en) | Ocular solutions | |
| Sanborn et al. | Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis: use of an intravitreal device | |
| ES2326550T3 (es) | Uso de un macrolido para restablecer la sensacion corneal. | |
| Wadood et al. | Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification | |
| US20060228394A1 (en) | Ocular solutions | |
| Eperon et al. | A biodegradable drug delivery system for the treatment of postoperative inflammation | |
| JP2024103501A (ja) | 被験体における虚血再灌流障害のリスクを予防又は軽減するための神経保護特性がある薬物の使用 | |
| İnan et al. | Prevention of posterior capsule opacification by retinoic acid and mitomycin | |
| US20130156841A1 (en) | Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids | |
| KR102860024B1 (ko) | 이나보글리플로진을 포함하는 안질환의 예방 또는 치료용 약학적 조성물 | |
| HK40049263A (en) | Methotrexate for proliferative vitreoretinopathy | |
| HK40049263B (en) | Methotrexate for proliferative vitreoretinopathy | |
| HK1236395A1 (en) | Methotrexate for proliferative vitreoretinopathy | |
| HK1236395B (en) | Methotrexate for proliferative vitreoretinopathy | |
| US11260104B2 (en) | Carrier composition for eye drops and pharmaceutical composition including the same | |
| AU2019204106A1 (en) | Intraocular drug delivery device and associated methods |